--- title: "Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat" type: "News" locale: "en" url: "https://longbridge.com/en/news/295643755.md" description: "Mereo BioPharma and Sentynl Therapeutics signed a licensing deal for alvelestat. Sentynl acquires exclusive US commercial rights via an option, paying a non-refundable fee. Upon exercise, Mereo receives up to $40m upfront/R&D payments, up to $435m in milestones, and double-digit royalties. Sentynl holds global manufacturing rights and funds Phase III development starting early 2027. Alvelestat targets AATD-LD with orphan drug designations." datetime: "2026-08-12T09:14:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295643755.md) - [en](https://longbridge.com/en/news/295643755.md) - [zh-HK](https://longbridge.com/zh-HK/news/295643755.md) generator: "portal-rs" --- # Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser. ### Related Stocks - [MREO.US](https://longbridge.com/en/quote/MREO.US.md) ## Related News & Research - [Wall Street banks set for banner year as Anthropic, SpaceX IPOs generate US$1 billion in fees](https://longbridge.com/en/news/306386521.md) - [Anthropic PBC (ANT) Claims Claude Solved The 167 Year Old Riemann Hypothesis](https://longbridge.com/en/news/306374461.md) - [Wall St Week Ahead-'Black Friday' brings consumer spending into focus for AI-rocked market](https://longbridge.com/en/news/306395310.md) - [e.l.f. Beauty (ELF) Could Be 21% Undervalued As Sports And Retail Reach Expand](https://longbridge.com/en/news/306384935.md) - [American Battery Technology (ABAT) Stock Looks Above Fair Value On Current Sales](https://longbridge.com/en/news/306379412.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**